From Wikipedia, the free encyclopedia
  (Redirected from Cjc-1295)
Jump to: navigation, search
Clinical data
Legal status
  • Investigational
Routes Subcutaneous injection
CAS number 863288-34-0
ATC code None
PubChem CID 56841945
Chemical data
Formula C152H252N44O42 
Molecular mass 3367.90 g/mol

CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It was invented by ConjuChem, a Canadian biotechnology company.

One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.[1]


The reason why CJC-1295 possesses the ability to lengthen the half-life within the active agent has to do with the scientific process known as bioconjugation. This technology, which is relatively new, is defined by its ability to take a reactive group and bond it to a peptide. This attachment causes a reaction with a nucleophilic unit, a typically partially molecule that is found within the bloodstream of an animal test subject. This reaction in turn causes a more stable bond to occur. This specific peptide has an especially high attraction to albumin, a globular protein that is soluble in water. This affinity prohibits natural degradation, which in turn increases the peptide’s half-life. Additionally, clinical research performed on animal test subjects has thus far shown that there have been no signs of DPP-IV degradation present when CJC-1295 was introduced.[2]

See also[edit]